Notable Labs

Notable Labs Depreciation & Amortization

The Depreciation & Amortization of Notable Labs (NTBLQ) as of Oct 31, 2026 is 160,000.00 USD. In the previous year, Depreciation & Amortization was 130,000.00 USD — a change of 23.08% (higher).

Depreciation & Amortization

160,000.00USD

YoY

23.08%

Last updated:

Depreciation & Amortization of Notable Labs is 2017 160,000.00 USD. Depreciation & Amortization of Notable Labs was 2016 130,000.00 USD. It decreases by 23.08% higher compared to the previous year.

The Notable Labs Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2014
140,000.00 USD
Jan 1, 2015
120,000.00 USD
Jan 1, 2016
130,000.00 USD
Jan 1, 2017
160,000.00 USD
The Notable Labs Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
160,000.00USD+23.08%
130,000.00USD+8.33%
120,000.00USD-14.29%
140,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Depreciation & Amortization of Notable Labs is 160,000.00 USD in 2017.

Depreciation & Amortization of Notable Labs changed from 130,000.00 USD to 160,000.00 USD, representing a 23.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Depreciation & Amortization Notable Labs since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's Notable Labs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Notable Labs

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Notable Labs